Recombinant Human Cyclin-dependent kinases regulatory subunit 1 (CKS1B)

Code CSB-YP005464HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP005464HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP005464HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP005464HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
CKS1B
Uniprot No.
Alternative Names
CDC2 associated protein CKS1; CDC28 protein kinase 1; CDC28 protein kinase 1B; CDC28 protein kinase regulatory subunit 1B ; Cell division control protein CKS1; CKS 1; CKS-1; CKS1; CKS1_HUMAN; Cks1b; Ckshs1; Cyclin dependent kinases regulatory subunit 1; Cyclin-dependent kinases regulatory subunit 1; NB4 apoptosis/differentiation related protein; PNAS 143; PNAS 16; PNAS 18
Species
Homo sapiens (Human)
Expression Region
2-79
Target Protein Sequence
SHKQIYYSD KYDDEEFEYR HVMLPKDIAK LVPKTHLMSE SEWRNLGVQQ SQGWVHYMIH EPEPHILLFR RPLPKKPKK
Protein Length
Full Length of Mature Protein
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.
Gene References into Functions
  1. miR-204 inhibits cell proliferation in gastric cancer by targeting CKS1B, CXCL1 and GPRC5A. PMID: 29283424
  2. Multiple myeloma patients with CKS1B amplification are more likely to have additional high-risk cytogenetic abnormalities and a shorter PFS and OS after an auto-HCT. PMID: 27638366
  3. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CKS1B. PMID: 27270326
  4. High CKS1B gene expression correlates with disease onset and progression of Multiple Myeloma and associated with more extra copies of 1q21. PMID: 28766538
  5. we overexpressed CKS1B in multiple cell lines and found increased sensitivity to PLK1 knockdown and PLK1 drug inhibition. Finally, combined inhibition of WEE1 and PLK1 results in less apoptosis than predicted based on an additive model of the individual inhibitors, showing an epistatic interaction and confirming a prediction of the yeast data. PMID: 27558135
  6. High expression of Cks1 was significantly associated with lymph node metastasis and survival status in nasopharyngeal carcinoma PMID: 28061788
  7. Results show that Cks1 and Cks2 promoted proliferation and prevented apoptosis of hepatocellular carcinoma HepG2 cells. PMID: 26531156
  8. Specifically, CKS1B and MAP2K5 significantly inhibited hepatitis C viral RNA replication. PACSIN1, by contrast, inhibited hepatitis C virus infection by decreasing the level of viral protein p7. PMID: 24205826
  9. Regulation of Cks1 protein stability is crucially dependent on specific tyrosine and lysine residues which are potential sites for post-translational modifications. PMID: 25353373
  10. We conclude that perturbing the Hsp90 pathway could provide a useful therapeutic strategy in tumors driven by Cks1 overexpression PMID: 25544127
  11. Our results suggest a role for CKS1B in the multiple step process of progression of MGUS to MM and show that CKS1B copy gain has a more significant prognostic value than its overexpression. PMID: 24973170
  12. CKS1 mRNA and protein expression were increased in esophageal carcinoma. Overexpression of CKS1 was associated with higher grad, regional lymph node invasion, and neoplastic embolus. CKS1 was negatively associated with the p27(kip1) level in the tumor. PMID: 23301842
  13. We demonstrated that high expression of CKS1B immunostaining can be one potent prognostic factor for disease-specific survival, metastasis-free survival, and local recurrence-free survival in patients with nasopharyngeal carcinoma. PMID: 23879533
  14. Anaplastic multiple myeloma was associated with significantly higher prevalence of CKS1B amplification than non-anaplastic multiple myeloma. PMID: 24169086
  15. CKS1B analysis predicts 1q21 amplification and adverse outcome for risk stratification of patients with multiple myeloma. PMID: 20421271
  16. cyclin kinase subunit 1B nuclear expression detected by immunohistochemistry is an adverse prognostic factor for patients with multiple myeloma treated with bortezomib therapy PMID: 22047644
  17. Cks1 is overexpressed in esophageal squamous cell carcinoma tissues. Overexpression correlates with increased radiotherapy resistance of esophageal squamous cell carcinoma. PMID: 22302047
  18. Overexpression of Cks1 or Cks2 in human mammary epithelial and breast cancer-derived cells, as well as in other cell types, leads to override of the intra-S-phase checkpoint. PMID: 21697511
  19. In hepatoma cells, Cks1 controlled IL-8 expression by targeting the NF-kappaB regulator IkappaBalpha, which led to NF-kappaB activation, via a p27-independent regulation of IkappaB kinase complex components. PMID: 21917729
  20. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. PMID: 20930946
  21. A significant CKS1B overexpression was observed in oral squamous cell carcinoma and lymph node metastases samples than in oral lichen planus or oral leukoplakia. PMID: 21117028
  22. Association between CKS1B protein overexpression and both polysomy and amplification was demonstrated in cutaneous squamous cell carcinoma PMID: 20737481
  23. CKS-1B is commonly expressed in mantle cell lymphoma, particularly in aggressive histologic variants, and may be involved in pathogenesis. PMID: 20688354
  24. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover. PMID: 19866239
  25. Overexpression of Cks1 and Cks2 is associated with the aggressive tumour behaviours of hepatocellular carcinoma. PMID: 19845855
  26. Weak cooperativity in the core causes a switch in folding mechanism between two proteins of the cks family. PMID: 12473461
  27. induction of Skp2 and Cks1 degradation in G1 represents a principal mechanism by which APC/C(Cdh1) prevents the unscheduled degradation of SCF(Skp2-Cks1) substrates and maintains the G1 state PMID: 15014502
  28. Cks1 overexpression may play an important role for oral squamous cell carcinoma development through Skp2-mediated p27 degradation PMID: 15579456
  29. analysis of the protein dynamics of Cks1 PMID: 15772084
  30. ubiquitin ligase subunit Cks1 is involved in p27Kip1 down-regulation and may have an important role in the development of aggressive tumor behavior in breast cancer. PMID: 16168119
  31. over-expression of CKS1B, mainly due to gene amplification, imparts a poor prognosis in MM, possibly as a result of enhanced degradation of p27Kip1. PMID: 16188652
  32. Cks1 expression level regulates melanoma cell growth, most likely through effects on cell proliferation. PMID: 16924241
  33. Results show that complex formation between Cks1 and Skp2 causes conformational changes in both proteins in regions distant from the respective binding sites. PMID: 16979657
  34. Generally, the observation that the potential oncogene Cks1 is downregulated by the tumor suppressor p53 corresponds well with the idea that p53 employs multiple ways in order to halt the cell cycle. PMID: 17377499
  35. Cks1 expression was only correlated with tumor size in renal cell carcinoma. PMID: 18922157
  36. These data suggest that Cks1 is an oncogene in the 1q21 amplicon and plays an important role for breast cancer development. PMID: 19161979

Show More

Hide All

Protein Families
CKS family
Database Links

HGNC: 19083

OMIM: 116900

KEGG: hsa:1163

STRING: 9606.ENSP00000471505

UniGene: Hs.374378

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1